Pilgrim Partners Asia Pte Ltd Invests $67,000 in Moderna, Inc. (NASDAQ:MRNA)

Pilgrim Partners Asia Pte Ltd bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 1,600 shares of the company’s stock, valued at approximately $67,000.

Several other institutional investors also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB grew its stake in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after buying an additional 587 shares during the last quarter. Compass Planning Associates Inc purchased a new position in shares of Moderna in the 4th quarter valued at approximately $37,000. Venturi Wealth Management LLC boosted its stake in Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares in the last quarter. Crowley Wealth Management Inc. purchased a new stake in Moderna during the 4th quarter worth approximately $41,000. Finally, MassMutual Private Wealth & Trust FSB increased its stake in Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after purchasing an additional 389 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of research analyst reports. Evercore ISI set a $50.00 price objective on shares of Moderna in a report on Friday, February 14th. Royal Bank of Canada reiterated a “sector perform” rating and set a $40.00 price target on shares of Moderna in a research note on Tuesday, February 18th. UBS Group reduced their price objective on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research note on Wednesday, February 19th. Citigroup began coverage on Moderna in a research report on Thursday, March 13th. They issued a “neutral” rating and a $40.00 target price on the stock. Finally, Morgan Stanley decreased their price objective on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 15th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $59.00.

Moderna Trading Down 2.4 %

Shares of NASDAQ MRNA opened at $25.11 on Friday. Moderna, Inc. has a 12-month low of $23.76 and a 12-month high of $170.47. The stock has a market cap of $9.71 billion, a P/E ratio of -2.71 and a beta of 2.23. The business’s fifty day simple moving average is $33.55 and its 200-day simple moving average is $43.01.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.